Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant TB

20 July 2026

Akagera Medicines press release

KIGALI, Rwanda, July 20, 2026 — Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing lipid-nanoparticle therapeutics and vaccines for infectious diseases that disproportionately affect the majority world, together with the TASK Clinical Research Center in South Africa, today announced positive results from the single-ascending-dose (SAD) portion of the first-in-human Phase 1 study of AKG-100, the company’s investigational long-acting intravenous (IV) therapeutic being developed to transform the treatment of TB including drug-resistant TB (DR-TB).

The SAD study evaluated single IV doses of AKG-100 across a range of dose levels in 40 healthy volunteers and 15 patients with pulmonary TB in a 14-day Early Bactericidal Activity (EBA) cohort. AKG-100 was well tolerated at every dose studied, up to and including the highest dose of 850 mg. The overall safety profile was favorable; no participants discontinued due to adverse events and most adverse events were mild and self-limiting.

Read the full press release here.

Source: PRNewswire